How government-dependent is REGENERON PHARMACEUTICALS, INC.?

In fiscal year 2025, US federal contract obligations equal at least -2.3% of REGENERON PHARMACEUTICALS, INC.'s reported revenue - $-331.7M in federal awards against $14.3B in revenue as filed with the SEC. In fiscal year 2024 the share was at least -0.0%.

Cite as: FACTANKER, https://factanker.com/entity/2dc9492b-8afa-424a-a63e-3c4cc18bafa8/government-dependency

Fiscal year	Revenue (SEC, as filed)	Federal obligations	Share	Data status
FY 2025	$14.3B	$-331.7M	≥ -2.3%	contracts only
FY 2024	$14.2B	$-1.4M	≥ -0.0%	contracts only

Evidence
Revenue FY 2025: evidence fact 1be0b51e… (SEC filing)
Federal obligations FY 2025: sum of 4 award records (USAspending bulk data)
Identity consolidation: CIK 0000872589 · LEI 549300RCBFWIRX3HYQ56 · UEI N3F9MH7E6HD6 - linked via evidence-backed same_as facts, see all facts of this organization

Methodology & sources
Revenue: company fiscal year, as filed with the SEC (XBRL concept per evidence fact). Obligations: US federal fiscal year of the award date, consolidated across all registrations of the corporate group. Computed in the database, precomputed weekly - never by a model. Sources: SEC EDGAR, USAspending (public domain).

Not claimed

The two periods do not align exactly: revenue follows the company's fiscal year, obligations the US federal fiscal year (Oct-Sep).
Years marked 'contracts only': grant/assistance awards are not yet loaded - the share is a floor, not the full figure.
Fiscal years without a share: obligations base files not yet loaded; a missing value means missing load, not zero government business.
Obligations are amounts obligated, not amounts paid out.
The share consolidates all registrations of the corporate group via evidence-backed identity links (same_as facts).

REGENERON PHARMACEUTICALS, INC. - all facts · Use this metric in your own models: JSON/API · API/MCP quickstart